AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03145714
Drug: Maintainance of anesthesia with Intravenous Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
Trial: NCT03145714
Drug: Maintainance of anesthesia with Intravenous Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
Trial: NCT02778919
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02632136
Drug: TAP Block Group
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
Trial: NCT02632136
Drug: Peri-Portal Block Group
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
Trial: NCT02596334
Drug: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg
RxNorm normalized name: abacavir / dolutegravir / lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02596334
Drug: dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04099888
Drug: Fimaporfin and Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m²) and intraluminal laser light application. Up to 2 PCI treatments will be given.
Trial: NCT01215409
Drug: Vardenafil (Levitra, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
Trial: NCT00813306
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 mg oral solution, 1 single dose
Trial: NCT00813306
Drug: AZD2066
RxNorm normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
Trial: NCT03604198
Drug: relacorilant
RxNorm normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT125134 is supplied as capsules for oral dosing.
Trial: NCT00013546
Drug: TMTDS
RxNorm normalized name: TMTM
DrugBank: Tetramethylthiuram monosulfide (DB14178)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04705142
Drug: MgSo4
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before and during administration of MgSO4, B.P, Capillary refill time, Heart rate and respiratory rate will be assessed closely i-e on 10 minutes interval, infusion of MgSO4 will be give over 30 minutes and baby will be monitored every 15 minutes interval after completion of infusion as well for 1 hour.
Trial: NCT02238366
Drug: triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
Trial: NCT02677532
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g every 8 hours
Trial: NCT02677532
Drug: Levobupivacaine wound infiltration
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 10 ml levobupivacaine 0.5%
Trial: NCT02677532
Drug: Levobupivacaine epidural bolus
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural bolus of 10 ml 0.25% levobupivacaine
Trial: NCT02388048
Drug: Ibrutinib + ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03805477
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
Trial: NCT03629925
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, Q3W, day1, I.V.; consecutive cycles
Trial: NCT03629925
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.
Trial: NCT03629925
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Trial: NCT03629925
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.
Trial: NCT03387761
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg
Trial: NCT03387761
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg
Trial: NCT02677532
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous slow bolus of 10 mg morphine
Trial: NCT02677532
Drug: Levobupivacaine plus sufentanil epidural infusion
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
Trial: NCT02677532
Drug: Levobupivacaine wound infusion
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
Trial: NCT00430079
Drug: etanidazole
RxNorm normalized name: Etanidazole
DrugBank: Etanidazole (DB12736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00802100
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tablets of 10 to 30 mg
Trial: NCT00802100
Drug: Perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tablets of 8 to 24 mg
Trial: NCT00802100
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily tablets of 10 to 30 mg
Trial: NCT00802100
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily tablets of 850 to 2550 mg
Trial: NCT00802100
Drug: Benztropine
RxNorm normalized name: Benztropine
DrugBank: Benzatropine (DB00245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tablets of 1 to 2 mg
Trial: NCT02283775
Drug: Isatuximab SAR650984
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Trial: NCT02283775
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:capsules Route of administration: oral
Trial: NCT02283775
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
Trial: NCT02024087
Drug: Dalantercept plus sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
Trial: NCT00043771
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03614364
Drug: herzuma
RxNorm normalized name: Herzuma
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
Trial: NCT00261469
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00091442
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
Trial: NCT00091442
Drug: DOXIL
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Trial: NCT00092989
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 1 dose
Trial: NCT04377620
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinb administered BID approximately 12 hours apart
Trial: NCT04312204
Drug: Sintilimab combined with Gemcitabine and Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will received Gemcitabine1000mg/m2(d1,d8)(iv)+carboplatin AUC 5 (d1)(iv),4 cycles, Sintilimab 200 mg (3mg/kg when the weight \<40kg ) (d1) (iv) in one cycle every 3 weeks, until PD or death.~Radiological examinations (according to the RECIST 1.1 criteria) at baseline will be repeated for tumor response evaluation following every two cycles of chemotherapy. Patients will be followed up to 30 days after the last dose of study chemotherapy, and then every 3 months.
Trial: NCT02252913
Drug: Volitinib
RxNorm normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02252913
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection
Trial: NCT02997800
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP \>20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
Trial: NCT02997800
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) \>20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP \>20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Trial: NCT00495365
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04190693
Drug: IMCY-0098 or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Long-term follow-up
Trial: NCT03369093
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily doses of injectable amoxicillin
Trial: NCT01282047
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
Trial: NCT00214110
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01238237
Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
Trial: NCT03495427
Drug: F-DCFPyL Injection
RxNorm normalized name: DCFPyL F-18
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
Trial: NCT03775486
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
Trial: NCT03775486
Drug: Placebo for Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching tablet
Trial: NCT03775486
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
Trial: NCT03775486
Drug: Nab-paclitaxel+carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy (squamous and non-squamous patients)
Trial: NCT03775486
Drug: Gemcitabine+carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy (squamous patients only)
Trial: NCT03775486
Drug: Pemetrexed+carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of Care chemotherapy (non-squamous patients only)
Trial: NCT03775486
Drug: Gemcitabine+cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of Care chemotherapy (squamous patients only)
Trial: NCT03775486
Drug: Pemetrexed+cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care chemotherapy (non-squamous patients only)
Trial: NCT02571777
Drug: salmeterol/fluticasone
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00429364
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan .3 - 1.4 mg/kg
Trial: NCT00429364
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol .5 - 4 mg/kg
Trial: NCT03287609
Drug: Evolocumab 140 mg/mL
RxNorm normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three injections with pre-filled auto-injector pen at day 1 and at week 4.
Trial: NCT02257008
Drug: BILR 355 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257008
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02257008
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02257008
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01050647
Drug: 17-Hydroxyprogesterone Caproate
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly injections of 17-hydroxyprogesterone caproate.
Trial: NCT04603456
Drug: Lacteol fort
RxNorm normalized name: Lacteol
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacteol fort is a drug containing lactobacilli
Trial: NCT04603456
Drug: Standardized Timothy Grass Pollen
RxNorm normalized name: Standardized timothy grass pollen
DrugBank: Phleum pratense pollen (DB10394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
Trial: NCT01273181
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720,000 IU/kg every 8 hours for a maximum of 15 doses
Trial: NCT01273181
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
Trial: NCT00337077
Drug: eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00003797
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02129348
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02327195
Drug: Methylphenidate HCl
RxNorm normalized name: methylphenidate HCl
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
Trial: NCT02566824
Drug: Methylphenidate or amphetamine product
RxNorm normalized name: amphetamine Oral Product
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
Trial: NCT00973193
Drug: panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
Trial: NCT00219323
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01184560
Drug: Sibutramine
RxNorm normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Trial: NCT01184560
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily